Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 1.00 |
| ▸ | SRC | P12931 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 7/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 7/20 | 1.00 |
| ▸ | EGFR | P00533 | 5/20 | 0.82 |
| ▸ | ABL1 | P00519 | 6/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.79 |
| ▸ | WEE1 | P30291 | 4/20 | 0.79 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.79 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.79 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.79 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.79 |
| ▸ | PAK4 | O96013 | 1/20 | 0.79 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.79 |
| ▸ | FYN | P06241 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102543 | 0.93 | FGFR1 (0.86) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| SCHEMBL5764000 | 0.90 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| SCHEMBL2083345 | 0.90 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| SCHEMBL5762332 | 0.90 | FGFR1 (0.81) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| SCHEMBL15984315 | 0.89 | WEE1 (0.85) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| Pd-0166285 SCHEMBL30250248 | 0.89 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| Pd-0166285 SCHEMBL133914 | 0.89 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| SCHEMBL5764062 | 0.88 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| Pd-0166285 SCHEMBL30276696 | 0.88 | FGFR1 (0.98) | FGFR1SRCPDGFRBPDGFRAEGFR | |
| Pd-0166285 SCHEMBL15106017 | 0.88 | FGFR1 (0.98) | FGFR1SRCPDGFRBPDGFRAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233174-B1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | UNIV EMORY (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2233174-A1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | Emory University (US) | 2010-09-29 | — | — | EP | claimed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | claimed |
| EP-1907411-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC. (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2007008917-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-2233174-B1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | UNIV EMORY (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8765777-B2 | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection | EMORY UNIVERSITY (US) | 2014-07-01 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2260849-A1 | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection | Emory University (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2233174-A1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | Emory University (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | FGFR1 4698/4885SRC 2604/4885PDGFRB 3462/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | FGFR1 118/4885SRC 9/4885PDGFRB 16/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | FGFR1 184/4885SRC 69/4885PDGFRB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.